1-(6-(hexyloxy)naphthalen-2-yl)ethanone | 1162128-78-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(6-(hexyloxy)naphthalen-2-yl)ethanone
• 英文别名: 1-(6-Hexoxynaphthalen-2-yl)ethanone
• CAS: 1162128-78-0
• 化学式: C₁₈H₂₂O₂
• 分子量: 270.371
• InChiKey: RUWXUNRHRDQOGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 1-(6-(hexyloxy)naphthalen-2-yl)ethanone 、 盐酸二甲胺 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 反应 2.0h， 以61%的产率得到3-(dimethylamino)-1-(6-(hexyloxy)naphthalen-2-yl)propan-1-one
  参考文献：
  名称：

  Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

  摘要：

  We have previously reported the discover), and preliminary structure activity relationships of a series of beta-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive Survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity, Finally, utilization of airline moieties having low pK(a)'s resulted in lowered ion channel activity without any loss of pharmacological activity.

  DOI：

  10.1021/jm9002704
• 作为产物：
  描述：

  溴己烷 、 6-乙酰基-2-萘酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 1-(6-(hexyloxy)naphthalen-2-yl)ethanone
  参考文献：
  名称：

  Improvement of Pharmacological Properties of Irreversible Thyroid Receptor Coactivator Binding Inhibitors

  摘要：

  We have previously reported the discover), and preliminary structure activity relationships of a series of beta-aminoketones that disrupt the binding of coactivators to TR. However, the most active compounds had moderate inhibitory potency and relatively high cytotoxicity, resulting in narrow therapeutic index. Additionally, preliminary evaluation of in vivo toxicology revealed a significant dose related cardiotoxicity. Here we describe the improvement of pharmacological properties of thyroid hormone receptor coactivator binding inhibitors. A comprehensive Survey of the effects of substitutents in key areas of the molecule was carried out based on mechanistic insight from the earlier report. This study revealed that both electron withdrawing and hydrophobic substituents on the aromatic ring led to higher potency. On the other hand, moving from an alkyl to a sulfonyl alkyl side chain led to reduced cytotoxicity, Finally, utilization of airline moieties having low pK(a)'s resulted in lowered ion channel activity without any loss of pharmacological activity.

  DOI：

  10.1021/jm9002704

文献信息

• Lipopeptide Compounds and Their Use
  申请人：Boyce Rustum S.

  公开号：US20110224129A1

  公开（公告）日：2011-09-15

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.

  本发明一般涉及治疗化合物领域，更具体地涉及包括带有脂肪侧链的环肽的某些脂肽化合物（为方便起见，在本文中统称为“LP化合物”），其中，这些化合物具有抗微生物作用，特别是抗菌作用。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，在体外和体内提供抗微生物功能，特别是抗菌功能，以及在治疗由微生物介导的疾病和病症方面的用途，特别是由抗菌功能缓解的细菌疾病，可选地与另一药剂（例如另一抗菌剂）结合使用。
• LIPOPEPTIDE COMPOUNDS AND THEIR USE
  申请人：Uniquest PTY Limited

  公开号：EP2350119B1

  公开（公告）日：2014-10-29
• US6743777B1
  申请人：——

  公开号：US6743777B1

  公开（公告）日：2004-06-01
• US7790744B2
  申请人：——

  公开号：US7790744B2

  公开（公告）日：2010-09-07
• US8921309B2
  申请人：——

  公开号：US8921309B2

  公开（公告）日：2014-12-30